2,2,6,6-tetramethyl-heptan-3-ol | 69897-43-4

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,2,6,6-tetramethyl-heptan-3-ol
• 英文别名: 2,2,6,6-Tetramethylheptan-3-ol
• CAS: 69897-43-4
• 化学式: C₁₁H₂₄O
• 分子量: 172.311
• InChiKey: YGYDJJLWFNGEHK-UHFFFAOYSA-N

物化性质

• 熔点：
  58-59 °C
• 沸点：
  194.7±8.0 °C(Predicted)
• 密度：
  0.828±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,2,6,6-tetramethyl-heptan-3-ol 、 1-Alapha-萘异氰酸酯 生成 [1]naphthyl-carbamic acid-(1-tert-butyl-4,4-dimethyl-pentyl ester)
  参考文献：
  名称：

  Whitmore et al., Journal of the American Chemical Society, 1941, vol. 63, p. 647

  摘要：

  DOI：
• 作为产物：
  描述：

  2,2-二甲基戊酸 在 氯化亚砜 、 乙醚 作用下， 生成 2,2,6,6-tetramethyl-heptan-3-ol
  参考文献：
  名称：

  Whitmore et al., Journal of the American Chemical Society, 1941, vol. 63, p. 647

  摘要：

  DOI：

文献信息

• Vitamin D Receptor Modulators
  申请人：Bunel Emilio Enrique

  公开号：US20090018058A1

  公开（公告）日：2009-01-15

  The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating and psoriasis.

  本发明涉及一种新型的非类固醇二芳基化合物，具有维生素D受体（VDR）调节和治疗牛皮癣的作用。
• VITAMIN D RECEPTOR MODULATORS
  申请人：Bunel Emilio Enrique

  公开号：US20090227604A1

  公开（公告）日：2009-09-10

  The present invention relates to novel, non-secosteroidal, diaryl compounds with vitamin D receptor (VDR) modulating activity that are less hypercalcemic than 1a,25 dihydroxy vitamin D3. These compounds are useful for treating bone disease and psoriasis.

  本发明涉及一种新的、非次级甾体、二芳基化合物，具有维生素D受体（VDR）调节活性，比1a,25二羟基维生素D3的高钙血症更少。这些化合物对治疗骨病和牛皮癣有用。
• NOVEL FUSED PYRAZOLE DERIVATIVES AND THEIR USE AS ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
  申请人：Bolea Christelle

  公开号：US20130252944A1

  公开（公告）日：2013-09-26

  The present invention relates to novel compounds of Formula (I), wherein M, A and Y are defined as in Formula (I); invention compounds are modulators of metabotropic glutamate receptors—subtype 4 (“mGluR 4 ”) which are useful for the treatment or prevention of central nervous system disorders as well as other disorders modulated by mGluR 4 receptors. The invention is also directed to pharmaceutical compositions and the use of such compounds in the manufacture of medicaments, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR 4 is involved.

  本发明涉及式(I)的新型化合物，其中M、A和Y如式(I)中所定义；发明化合物是代谢型谷氨酸受体亚型4（“mGluR4”）的调节剂，可用于治疗或预防中枢神经系统疾病以及其他受mGluR4受体调节的疾病。本发明还涉及制药组合物以及使用这种化合物制造药物的用途，以及使用这种化合物预防和治疗涉及mGluR4的疾病的用途。
• Zinc-modified cyanoborohydride as a selective reducing agent
  作者：Sunggak Kim、Chang Ho Oh、Jae Suk Ko、Kyo Han Ahn、Yong Jin Kim

  DOI：10.1021/jo00211a028

  日期：1985.5
• IAP BINDING COMPOUNDS
  申请人：Condon Stephen M.

  公开号：US20090048183A1

  公开（公告）日：2009-02-19

  IAP binding molecules and compositions including these are disclosed. The IAP binding molecules interact with IAPs (inhibitor of apoptosis proteins) in cells and may be used to modify apoptosis in cells treated with such molecules. Embodiments of these compounds have a K d of less that 0.1 micromolar. Methods of using these IAP binding molecules for therapeutic, diagnostic, and assay purposes are also disclosed.